Order byBest matchMost fresh

Lilly sues 2 compounders over copies of weight-loss drugs

Digest more
Top News
Impacts
Reuters |
Lilly said Strive's tirzepatide products, which come in standard doses added with vitamin B12 or glycine, are falsely suggested to be safer and more effective than FDA-approved medicines.
Business Insider |
Moreover, Bank of America also published bearish guidance, given that the company is expected to stop compounded semaglutide drug sales by May 22nd.

Read more on News Digest

Lilly sues two compounders over copies of weight-loss drugs
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ingredient in its popular weight-loss and diabetes medicines.
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Key Takeaways Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.The treatments will each cost $1,
Eli Lilly weight loss therapy added to Hims & Hers platform
Shares of Hims & Hers Health (NYSE:HIMS) traded higher on Tuesday after the telehealth company announced the addition of branded versions of Eli Lilly’s (NYSE:LLY) popular weight loss therapy tirzepatide for sale on its platform.
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.
Pharmaceutical Technology9d
Trump tariffs drive pharma manufacturing to US but risk inflation and disruption
Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more manufacturing capacity.
Where Will Eli Lilly Be in 1 Year?
The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.
Yahoo Finance9d
What’s Next for the Equity Markets?
The Fed has emphasized that tariff-related inflation is likely transitory. Futures markets anticipate two interest rate cuts this year, with a 50% chance of a third, sparking demand in Treasury ...
NBC DFW10d
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...
Feedback